Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

被引：6
|
作者：
Hotta, Katsuyuki [1 ,2 ]
Ninomiya, Kiichiro [1 ]
Ichihara, Eiki [1 ]
Kiura, Katsuyuki [1 ]
机构：
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 01期
基金：
日本学术振兴会;
关键词：
Lung cancer; Treatment; Re-biopsy; CISPLATIN-BASED CHEMOTHERAPY; LOW-VOLUME HYDRATION; SPATIOTEMPORAL T790M HETEROGENEITY; EGFR-MUTANT; PROSPECTIVE FEASIBILITY; OPEN-LABEL; EXPRESSION; MUTATIONS; ALECTINIB; 1ST-LINE;
D O I：
10.1007/s10147-018-1344-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. Thisreview reports that the significance of a re-biopsy varies depending on the clinical situation.
引用
收藏
页码：41 / 45
页数：5
相关论文
共 50 条
  • [1] Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice
    Katsuyuki Hotta
    Kiichiro Ninomiya
    Eiki Ichihara
    Katsuyuki Kiura
    International Journal of Clinical Oncology, 2019, 24 : 41 - 45
  • [2] Re-biopsy of twelve non small cell lung cancer (NSCLC) cases
    Tanaka, Tae
    Fumita, Soichi
    Okamoto, Kunio
    Shintani, Ryota
    Kiyokawa, Hirohumi
    Hayashi, Hidetoshi
    ANNALS OF ONCOLOGY, 2015, 26 : 113 - 114
  • [3] Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer
    Keisuke Kirita
    Takehiro Izumo
    Yuji Matsumoto
    Yoshihisa Hiraishi
    Takaaki Tsuchida
    Lung, 2016, 194 : 371 - 378
  • [4] Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer
    Kirita, Keisuke
    Izumo, Takehiro
    Matsumoto, Yuji
    Hiraishi, Yoshihisa
    Tsuchida, Takaaki
    LUNG, 2016, 194 (03) : 371 - 378
  • [5] Pulmonary re-biopsy in non-small-cell lung cancer (NSCLC) locally advanced or metastatic with EGFR-T790M resistance.
    Torricelli, Elena
    Mazzoni, Francesca
    Pasini, Valeria
    Innocenti, Margherita
    Bargagli, Elena
    Corbetta, Lornezo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [6] Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?
    Sibille, Anne
    Wauters, Isabelle
    Vansteenkiste, Johan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 529 - 539
  • [7] Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
    Robert Pirker
    Martin Filipits
    Cancer and Metastasis Reviews, 2016, 35 : 141 - 150
  • [8] Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
    Pirker, Robert
    Filipits, Martin
    CANCER AND METASTASIS REVIEWS, 2016, 35 (01) : 141 - 150
  • [9] Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
    Wang, Hanping
    Zhang, Li
    Si, Xiaoyan
    Zhang, Xiaotong
    Wang, Mengzhao
    ONCOTARGETS AND THERAPY, 2018, 11 : 7513 - 7519
  • [10] Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
    Laura Ortega-Granados, Ana
    Artal-Cortes, Angel
    Aguiar-Bujanda, David
    Oramas, Juana
    Luis Firvida, Jose
    De Castro, Javier
    Campillo Fuentes, Juana
    Gordo, Rocio
    Galan, Raquel
    Trigo, Jose
    ANTICANCER RESEARCH, 2019, 39 (03) : 1317 - 1328
12345